Hematology and Blood Disorders

Gene Therapy and Genetic Engineering in Hematology

The Gene Therapy and Genetic Engineering in Hematology track at the 21st Global Summit on Hematology and Blood Disorders (Blood Disorder 2025) will explore transformative advancements in genetic approaches for treating hematologic conditions. Researchers are invited to submit abstracts focusing on the latest developments in gene editing technologies, such as CRISPR, and their applications in curing genetic blood disorders like sickle cell disease and thalassemia. The track will feature presentations on novel gene therapies, innovative genetic engineering techniques, and their preclinical and clinical outcomes.

Attendees can expect detailed insights into cutting-edge research, practical applications of gene-based treatments, and the challenges and successes in translating these innovations into clinical practice. Interactive discussions with leading experts will provide deeper understanding and stimulate dialogue on the future of genetic therapies in hematology. Additionally, networking opportunities will allow participants to engage with pioneers in the field, fostering potential collaborations and enhancing the collective knowledge base. This track aims to advance understanding of genetic interventions and their potential to revolutionize the treatment landscape for hematologic disorders.